CURRENT SCENARIO OF DIABETIC MELLITUS WITH RECENT DRUG DEVELOPMENT APPROACHES: A COMPREHENSIVE REVIEW

HIRA DAS[1], SOUMYADIP GHOSH[2*] DEBGOPAL GANGULY[1], SUMIT MALAKAR[1], PURNIMA BISWAS[1], DEBRAJ GHOSH[1], AYAN MAITY[1], KOUSIK MAHANTI[3], DIPARATI MANDAL[4]

[1]School of Pharmacy, Seacom Skills University, Bolpur, Birbhum, West Bengal-731236

[2*]Department of Pharmaceutics, Bengal School of Technology (A College of Pharmacy), Sugandha, Chuchura, Hooghly, 712102, West Bengal, India.

[3]School of Medical Sciences, Adamas University, Barasat, Kolkata, West Bengal- 700126

[4]Eminent College of Pharmaceutical Technology, Barasat, West Bengal- 700126

*Corresponding Author
Mr. Soumyadip Ghosh
Department of Pharmaceutics, Bengal School of Technology (A College of Pharmacy), Sugandha, Chuchura, Hooghly, 712102, West Bengal, India.

Ph no – 7406554275/ 9606746804
Email id – soumyadeep271@gmail.com
ORCID ID - 0000-0003-0177-1328

Abstract:

Diabetes Mellitus, sometimes known as diabetes, is a metabolic condition characterized by persistently high blood glucose levels. Fasting blood sugar levels between 70 and 110 mg/dL are regarded as normal, while blood sugar levels between 100 and 125 mg/dL are regarded as prediabetes and 126 mg/dL of higher are regarded as diabetes. Type 1 and type 2 diabetes mellitus represent the two main subtypes.

Diabetes mellitus, a long-term metabolic condition, is a major social, health, and economic issue that is spreading quickly over the world. Diabetes results from either an insufficient amount of insulin being created by the pancreas or from the body's cells failing to react appropriately to that insulin. The hormone insulin is in charge of facilitating the entry of food-derived glucose into cells for cellular energy utilization. Diabetes mellitus long-term metabolic condition is an essential social, health, and economic issue that is spreading quickly over the world. Brittle diabetes is the period used to narrate this clinical condition. Diabetes insipidus is a situation marked by increased excretion of diluted urine as a consequence of vasopressin deficit, AVP resistance, or excessive consumption of water.

According to estimates, this illness affected 537 million people worldwide in 2022 roughly 6.4% of the adult population. If there are no improvements in treatment or control, this number is projected to rise to 653 million people worldwide in 2030. Additionally, it has been demonstrated that nearly 50% of those who are considered to be diabetics do not receive a diagnosis until 10 years after the onset of the condition, demonstrating that the actual global prevalence of diabetes must be very high. Both Kinds of diabetes mellitus have different causes, which are discussed in this chapter.

KEYWORDS: Diabetes, Insulin, Antioxidants, Patients, oral antidiabetic treatment.

INTRODUCTION

Diabetes is a metabolic disease that affects the body's metabolism and is defined by excessive blood glucose levels. Over time, this condition can Couse major harm to the heart, blood vessels, eyes, kidneys, and nerves.

Blood sugar levels are persistently elevated in diabetics. This could be a result of insulin not producing enough, not producing enough, or not producing as effectively as it should. Type 1 Diabetes, which affects 5% of people and is an autoimmune illness, and type 2 diabetes, which affects 95% of people and is linked to obesity, are the two most prevalent types of the disease (Takiishi T et al., 2012). Other types of diabetes are extremely uncommon and are brought on by a single gene mutation, with gestational diabetes being the type that affects pregnant women.

The typical digestive process of human diets incisures the conversion of food into glucose. The amount of dissolved glucose in the blood increases as soon as glucose is transformed and enters the bloodstream. The glucose that has been dissolved is subsequently transported by the bloodstream to the body's numerous tissues and cells. Despite the fact that there may be glucose in the blood, neighboring cells cannot reach that glucose without the help of a chemical hormone called insulin. The cells can take in and use the glucose that is accessible because insulin works as a key to unlock the cells. In the presence of insulin, cells taken up glucose from the blood, causing blood sugar leaves the blood and enter the cells. Glucose can be thought of as being transported via insulin to reach cells from the bloodstream. Understanding that as insulin levels rise, blood sugar levels fall is crucial (because the sugar goes into the cells to be used for energy). One of the many organs in your body the pancreas manufactures, stores, and releases insulin into the bloodstream to lower glucose levels.

The purpose of the food we eat is to give the body nutrition and energy. However, diabetes mellitus is a condition in which your body is unable to absorb or utilize the energy generated by eating food. There are just two names that describe the symptoms of diabetes mellitus in humans: Naturally occurring hormones like insulin, which aid in the conversion of sugar to energy, is produced by the pancreas. In the event of diabetes mellitus, the pancreas produces little or no insulin. When this happens, the pancreas's ability to generate insulin is compromised. In addition to genetics and lifestyle, excessive abdominal fat is a major

contributing factor. Obesity, a sedentary lifestyle, family history, and (those over 45 are at increased risk) are among risk factors. Gestational diabetes is another risk factor.

In the absence of a stomach mechanical obstruction, gastroparesis is a syndrome marked by delayed gastric emptying. The three most common symptoms are postprandial satiety (Premature satiety) nausea and bloating. The majority of diabetes patients possessing gastroparesis have the disease for a minimum of ten years and frequently have retinopathy, neuropathy, and nephropathy. Independent of other characteristics including age, tobacco usage, alcohol use, or type of diabetes, diabetes gastroparesis may result in severe symptoms, nutritional compromise, impaired glucose management, and a poor quality of life. 6 to 12% of diabetes patients describe the signs and symptoms of gastroparesis (Camilleri M et al., 2013).

The lack of patients is the cause of apparent referral bias or brief follow-up times, studies on the natural history of gastroparesis have been rather modest. In light of the results, stomach emptying and accompanying symptoms have remained largely stable during a 12-year period or length of follow-up. After accounting for other conditions, gastroparesis was found to be unrelated to mortality during a lesson of 86 diabetes individuals who were followed for at least nine years (Tan AH et al., 2022).

Diabetes mellitus long-term metabolic condition is an essential social, health, and economic issue that is spreading quickly over the world. According to estimates, this condition affected 537 million people worldwide in 2021 roughly 13% among the full-aged population. The growth is primarily caused by the aging population and obesity. Additionally, it has been demonstrated that about 50% of those who are considered to be diabetics do not receive a diagnosis until 10 years after the commencement of the condition indicating that the true incidence of diabetes worldwide must be extremely high (Zimmet PZ et al., 2014).

Global epidemic proportions of diabetes mellitus, a chronic metabolic noncommunicable disease have been observed. In 2020, there were 422 million adults who had diabetes mellitus. As of today, there are 537 million public globals who have the disease and by 2030 and that number is perspective to emersion to 643 million. As of 2021, India had the second-highest number of public alive with diabetes mellitus (74.2 million), making it one of the epicenters of the world epidemic. Large populations of people with diabetes mellitus are also seen in other South Asian nations like Bangladesh, Pakistan, Sri Lanka, and Nepal. Additionally, there is a sizable diaspora of Asian Indian people living in countries like the UK, the USA, Mauritius, Fiji, Malaysia, Singapore, South Africa, and those in the Gulf region of the Middle East. The prevalence of diabetes mellitus among these individuals has been observed to be much greater than that of the local populations of the aforementioned nations. The good news is that research on the condition and its perplexity has risen along with the frequency of type 2 diabetes in India (Roth GA et al., 2017).

If there are improvements in treatment or control, this numeral is projected to rise to 459 million. The growth is primarily caused by the aging population and obesity (Hruby A et al., 2015).

DIABETES MELLITUS:

DEFINITION

'Diabetes' word derived from the Greek word 'Siphon and Implies' which made a lot of urine. The following phrase 'Mellitus' word originates from the Latin term 'Mel' means 'honey' and was employed due to the sweetness of the urine. Chronic diabetes is a metabolic illness known as hyperglycemia that is characterized by elevated blood sugar levels. It is lack of insulin the main cause. Insulin is secreted by β-cell of the pancreas to control blood glucose levels. Morbidity rates are both significantly increased as a result (Shanmugam VU et al., 2014).

The body is unable to metabolize carbohydrates conditions include type-1 and type-2 diabetes. Examples of diabetic conditions that may be reversible include prediabetes and gestational diabetes. Prediabetes happens when compared to normal blood sugar levels, blood sugar levels are greater. If nothing is done to stop it, prediabetes may manifest into diabetes. During pregnancy, gestational diabetes can develop. When the infant is delivered, though, it can disappear.

When blood glucose, commonly referred to as blood gravel, is excessively high, eventually diabetes may result. These statements imply that a person doesn't genuinely have diabetes or that their condition is milder, yet diabetes always has serious repercussions. Diabetes is occasionally suggested as "borderline diabetes" or "a touch of sugar" (Nahar K et al., 2021).

The body uses the food that is eaten to produce blood glucose, which is the body's main energy source. The hormone insulin is created by the pancreas, which aids in the transport of food-derived glucose into body cells for use as an energy source. The body can occasionally create either too little or no insulin, or it can utilize it improperly. After that, glucose is unable to enter your cells and remains in your blood.

DIABETES MELLITUS TYPES

According to 1980 WHO, published the first broadly recognized classification of diabetes mellitus& it is modified in the year 1985. Diabetes mellitus in its basic or idiopathic form which is the subject of our discussion is the most prevalent and significant type. The classification includes several forms of hyperglycemia along with the clinical stages and an etiological of many diabetes mellitus kinds. The new diabetes mellitus categorization includes stages that reflect the varying levels of hyperglycemia in unique patients with any of the morbidity processes that may lead to diabetes mellitus. There are four different forms of diabetes mellitus according to the current classification system: type 1 (IDDM), type 2 (NIDDM), gestational diabetes, and "other specific types". The old and new terms of insulin-dependent (IDDM) or non-insulin-dependent (NIDDM), which were proposed by the WHO in 1980 and 1985, have vanished (WHO Expert Committee 1999) (Singh N et al., 2016).



Figure 1. Types of Diabetes Mellitus (Nishimura R et al., 2022)

A. Type 1 diabetes

The source of type 1 diabetes is believed to be an autoimmune disease. This indicates that the beta cells in your pancreas that create insulin are wrongly attacked by and destroyed by your immune system. The harm is irreparable. The source of the attacks remains unclear. Environmental and genetic factors might both play a role. It is not thought that lifestyle variables are significant.

B. Type 2 diabetes

Type 2 diabetes is a condition that starts with insulin resistance. As a result, your pancreas produces more insulin until it can no longer meet the demand. This indicates that your body cannot utilize insulin effectively. Elevated blood sugar is therefore caused by a reduction in insulin production.

Diabetes type 2 is not known to have a specific etiology.

Some potential contributing elements are:

- Genetics
- Lifestyle that is more sedentary
- Obesity or increased weight

Additionally, there could be environmental and other health problems (Zheng Y et al, 2018).

C. Gestational diabetes

Gestational diabetes mellitus (GDM) is the term used to describe glucose intolerance that develops for early or is discovered during pregnancy. Women who develop Type1 diabetes mellitus while pregnant and women with undiagnosed asymptomatic. Type 2 diabetes mellitus that is discovered during pregnancy are classified with Gestational Diabetes Mellitus (GDM). The effects of intrauterine exposure to hyperglycemia are thought to be answerable for the phenomenon of the offspring of pregnant women with gestational diabetes being at greater likelihood and type 2 diabetes in later life (Plows JF et

al., 2018). Gestational diabetes mellitus associated with pregnancy may show symptoms and then go away after delivery.

D. Other types of diabetes

Diabetes LADA - Latent Adult-onset, the detection of diabetes-related autoantibodies, and the absence of a need for insulin therapy for a certain amount of time following diagnosis are the characteristics of autoimmune diabetes. It is increasingly apparent that certain people may have a slowly progressing form of Type 1 diabetes, which is characterized by the appearance of autoantibodies. After receiving a type 2 diabetes diagnosis, some people quickly become insulin-dependent; these people may develop LADA, a slowly progressing variant of type 1 diabetes. Diabetes MODY often referred to as young-onset maturity-onset diabetes, is an autosomal dominantly inherited form of affliction caused by heterozygous mutations in several transcription factors engaged in the growth and maturation of pancreatic beta-cells (Buzzetti R et al., 2017). Autosomal inheritance, an early inception of diabetes, the preservation of endogenous insulin production, and the absence of symptoms collective with insulin resistance or the autoimmune process are all characteristics of MODY. Double diabetes is characterized by the occurrence of hyperglycemia in kids and juvenile adults along with a concomitant combination of indicators common to both type 1 and types 2 diabetes. Type 1 diabetes is inherently unstable, erection is a condition that is brittle. A small number of individuals with type 1 diabetes, mostly young women, experience chronically poor metabolic control, marked by a severe instability of glycemia values and frequent, erratic hypoglycemic or diabetic ketoacidosis episodes that cannot be attributed to mistakes made by the patients or the healthcare providers. These patients' quality of life is severely diminished, particularly as a consequence of the frequent acute occurrences, hospital stays, and brisk onset of chronic problems (Steenkamp DW et al., 2017). Brittle diabetes is the period used to narrate this clinical condition. Diabetes insipidus is a situation marked by increased excretion of diluted urine as a consequence of vasopressin deficit, AVP resistance, or an excessive consumption of water. When a kid is older and an adult, polyuria is defined as having a urine volume greater than 21/m2/24 hours, or around 150 ml/kg/24 hours at birth, 100–110 ml/kg/24 hours till age 2, and 40–50 ml/kg/24 hours in those older and more mature age groups. New-borns with diabetes mellitus: This condition develops throughout the first six months of livelihood.

CAUSES OF DIABETES MELLITUS

The heredity, family history, racial, body, physical condition, and environmental factors that influence you can all have an impact on the source of your diabetes. As the source of diabetes vastly is dependent on the person with the category, there is absolutely no one common cause that applies to all forms. Different category of diabetes has their unique cause.

Cause of type 1 diabetes

When the insulin-producing beta cells of the pancreas are attacked and destroyed at the resistant structure, the body's defining mechanism against infection, like type 1 diabetes develops (Szablewski L et al., 2014). Researchers believe that like type 1 diabetes is brought on by genetics along with potential environmental triggers like infections. To identify the root causes of like type 1 diabetes and potential treatments, research projects like Trial Net External link are being conducted.

Cause of type 2 diabetes

Numerous variables, including heredity and one's lifestyle, grant to the spread of like type 2 diabetes. Whether or not you engage in any physical activity and are morbidly obese, your probability of growth like type 2 diabetes increases. Type 2 diabetes patients frequently have excess weight, which can occasionally lead to insulin resistance. Also important is where the body fat is located. Type 2 diabetes, blood vessel, and heart disease problems are all associated with excess abdominal fat. View these Body Mass Index (BMI) graphs to determine whether your weight puts you in fear of type 2 diabetes.

Insulin resistance, which is characterized by poor insulin sensitivity in the muscle, liver, and fat cells, is the normal precursor of type 2 diabetes. Correspondingly, your body requires extra insulin to assist glucose enter cells. The pancreas initially builds extra insulin to reach the increased demand. When the pancreas is unable to produce enough insulin over time, blood glucose volume rise. The same genes that cause type 1 diabetes can do as well increase your fear of growing type 2 diabetes. The racial/ethnic groups are extra given to experience the condition, which tends to run in families such as American Indians, African Americans, Alaska Natives, Pacific Islanders, and Asian Americans (Ravussin E et al., 2002).

By boosting a person's propensity to gain weight or be obese, heredity tin as well raises their fear of growing type 2 diabetes.

Cause of gestational diabetes

The hormonal changes that take place during pregnancy are what causes gestational diabetes. Pregnancy-related chemicals from the placenta reduce the sensitivity of the cells through the upshot of insulin (Ahmed et al., 2018). During pregnancy, this may result in excessive blood sugar. Pregnant women which are obese as a choice and who put on too much heaviness through pregnancy are extra given to developing gestational diabetes.

Cause of other diabetes

There are numerous additional probable causes of diabetes. They consist of the accompanying:

Diabetes credible brought on by pancreatitis or pancreatectomy. A pancreatectomy and pancreatitis are both known to raise the chance of acquiring diabetes. A rare kind of

diabetes called “Steroid diabetes” develops if glucocorticoid medication is used for an expanded session of time (Nair S et al., 2021).

RISK FACTORS OF DIABETES MELLITUS

Type I diabetes

Type I diabetes is a concern to be cared caused by the non-immune reaction. Risk factors of type-1 diabetes are not as clear as for Pre-diabetes and Tybe-2 diabetes.

i. Family history - Having a parent, brother, or sister with type 1 diabetes.
ii. Age - Although type 1 diabetes can occur at any age, it typically does so in young children.

Type 2 diabetes

i. Are overweight.
ii. Are 45 years or older.
iii. Have Prediabetes.
iv. Are Physically active less than 3 times a week
v. Have a Parent, brother, or sister with 40 types 2 diabetes.
vi. Have ever had gestational draw diabetes.
vii. Having high blood Pressure.
viii. Having low HDL cholesterol and high triglyceride level.
ix. Being a smoker.
x. Having Polycystic ovary Syndrome.
xi. Having a generation of heart disease on stroke.

Gestational diabetes

i. Type 2 diabetes runs in the family.
ii. Being over 25 years of majority.
iii. Having overweight

SYMPTOMS

Those who experience any of the following diabetic symptoms should speak with a doctor about getting their blood sugar checked:

- A considerable of night-time urination (peeing).
- Feel very tired.
- Have very dry skin.
- An unusually high incidence of infections.
- Feel tingling or inertness in feet or hands.
- Experience sluggish healing sores.



Figure 2. Symptoms of Diabetes Mellitus (Lupattelli A et al., 2022)



Figure 3. Symptoms of Type I Diabetes (Lupattelli A et al., 2022)



Figure 4. Symptoms of Type II Diabetes (Lupattelli A et al., 2022)



Figure 5. Symptoms of Gestational Diabetes (Lupattelli A et al., 2022)

Symptoms of type 1 diabetes in infant or child

The typical illustration of a child with newly-onset type 1 diabetes is that of a young youngster who is piddling regularly, drinking copiously, degreasing weight& growing more & more lethargic and sicker. Diabetes may be to blame if a youngster who has been exsiccating at night and potty-trained begins to have accidents and wet the bed once more.

When children are given a diabetes diagnosis, they may occasionally already be in diabetes ketoacidosis (DKA). The frame can accumulate significant amounts of an acid known as ketones when there is a shortage of insulin. Diabetes Ketoacidosis is an important medical emergency that typically calls for inpatient care, insulin administration, and intravenous fluids. Some kids could have a time where they appear to be producing adequate insulin once more after diagnosis and the first few months of medication. This is known as the “Honeymoon Phase”. Though it may appear that their diabetes has been healed, they will eventually need to receive the right amounts of insulin to maintain a level of blood sugar within the usual range (Castellanos L et al., 2020).

TREATMENT OF DIABETES MELLITUS

[A] Oral Antidiabetic Drugs

Hyperglycemia inside like type 2 (non-insulin-dependent) diabetes mellitus is treated with oral anti-diabetic medications. In addition, non-pharmacological therapies such as nutrition,

exercise, and health education are used. Oral antidiabetic medications fall into the following categories: sulphonylureas, prandial insulin releasers (also called meglitinides), biguanide metformin, thiazolidinediones, and -glucosidase inhibitors (Bastaki S et al., 2005).



Figure 6. Classification of Oral Antidiabetic Drugs (Nishimura R et al., 2022)

Sulfonylureas (K_{ATP} Channel blockers)

Sulfonylureas are a category based on organic compounds that are utilized in agriculture and medicine. They are commonly used as type 2 diabetes medications because they are effective in controlling blood sugar volume. They work by boosting the weight of insulin that the pancreatic beta cells release. They work by boosting the amount of insulin that the pancreatic beta cells release. Because they can prevent plants from properly utilizing particular amino acids in their biosynthesis, a variety of sulfonylureas are also employed as herbicides. Interleukin 1 beta release from the NALP3 inflammasome is also experimentally inhibited next to the utilization of sulfonylureas. Part of about the drugs includes Tolbutamide, Glipizide, Gliclazide, and Glimepiride.

Mechanism of action

Sulfonylureas tie up toward and block the potassium channels (K) operating pancreatic beta cells that are ATP-sensitive. The beta-cell membrane depolarizes properly, and potassium outflow is reduced. Insulin release from the pancreatic beta cells is stimulated by membrane depolarization because it opens calcium channels, which results in calcium inflow and higher intracellular calcium levels. Whatever the blood sugar volume, sulfonylureas cause the release of insulin. The two proteins that make up K are a sulfonylurea receptor and Kir6.2, which creates the pore of the K channels (SUR) (Hiriart M et al., 2014).

Sulfonylureas vary in how well they close K channels and how well they bind to SUR subtype receptors. Glimepiride is not connected to cardiovascular safety issues because of the reduced affinity for the heart muscles compared to other sulfonylureas. Sulfonylureas also lower serum glucose levels by reducing glucagon release, reducing insulin metabolism inside the liver, and raising insulin sensitivity in peripheral tissues.

Adverse effects

- **Low blood Sugar (Hypoglycemia)**

  Sulfonylureas raise the fear concerns hypoglycemia by stimulating insulin production independently of blood glucose levels. There is some indication that glyburide carries elevated fear of hypoglycemia due to its longer half-life than

other sulfonylureas. Because of this, the ADA advises against using it in elderly patients and high-risk patients.

A review of treating low blood sugar levels can be found in hypoglycemia.

- **Weight gain**

  Some patients may gain weight after taking sulfonylureas. For further information, view the impacts of body weight.

- **Photosensitivity**

  Sulfonylureas could make you photosensitive. Submission through the sunlight should be kept to a minimum and sunscreen should be worn (Kutlubay Z et al., 2014).

- **Skin reactions**

  In roughly 1.5% of patients, skin reactions such as pruritus, erythema, urticaria, morbilliform (measles-like) eruptions, and maculopapular rashes have been documented. If the medication is used regularly, these reactions might pass quickly. There have also been reports of more severe responses such as exfoliative dermatitis, bullous development, and erythema multiforme. In the event of severe or enduring reactions, sulfonylureas should be stopped (Cahn A et al., 2015).

Meglitinide/D-phenylalanine analogs (K_{ATP} Channel blockers)

These drugs inhibit K_{ATP} channels and have an immediate and transient insulinemic effect. This class includes Repaglinide, Nateglinide.

Repaglinide

Repaglinide is a drug used to manage and treat Type 2 diabetes mellitus. It is a medication from the antihyperglycemic medicine class. This exercise describes the benefits of repaglinide as a helpful treatment like type 2 diabetes mellitus, also how it works and when it should not be used.

Mechanism of action

Repaglinide is an insulin secretagogue, which means that it interacts with receptors at length pancreatic beta cells to promote the release of insulin. Repaglinide attaches the SUR1 potassium channel, an ATP-dependent potassium channel found at interminably beta cells, along with causes it to close. Concurrent use of these treatments are not advised for the reason that the similarity between their mechanisms of action and those of sulfonylureas. Repaglinide exhibits a concentration-response relationship when glucose is present, with a peak secretory response of roughly 10 nmol/L. According to studies, repaglinide lowers postprandial glucose by around 5.8 mmol/L and fasting glucose by approximately 3.1 to 3.4 mmol/L (Allen TW et al., 1992).

Repaglinide has a half-life of below 60 minutes and is swiftly taken up. Repaglinide is particularly the best treatment for controlling postprandial glucose rises because of its rapid start and brief duration of action. Appropriately, it is advised to take it roughly 30 minutes

before a planned meal. The concurrent use of other treatments linked to liver metabolism should be taken into consideration because repaglinide is inactivated and eliminated through the liver.

Adverse effects

Hypoglycemia (7% contemplate 76 patients) and build-up (1.8 kg / 16 weeks) are the most frequently reported side effects of repaglinide monotherapy, respectively. The three units of the Whipple triad for hypoglycemia are the residence of hypoglycemic symptoms, the presence of true hypoglycemia (50 mg/dl), and the correction of the symptoms with the introduction of glucose (Gribble FM et al., 2003).

Studies indicate that using repaglinide with a mix escorted by thiazolidinedione increases the risk of peripheral enema, but reports of hypoglycemia are more common when repaglinide is cast off in conjunction with metformin.

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Dipeptidyl peptidase-4 inhibitors be a division about doctor authorization drugs used in combination escorted

diet and exertion to treat high blood sugar inside persons escorted like type 2 diabetes. The DPP-4 inhibitor category based on drugs includes Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, etc.

Mechanism of action

DPP-4 is a widely distributed enzyme that affects incretin hormones, primarily GLP-1 (glucagon-like peptide-1) along with GIP (gastric inhibitory peptide), whichever regulates insulin production with glucagon secretion to maintain glucose homeostasis. The small intestine's enteroendocrine L cells secrete the hormone GLP-1, which further down blood sugar by promoting the release of more insulin, lowering glucagon levels, and delaying the emptying of the stomach. Below 2 minutes make up its half-life. Neuroendocrine K-cells secrete the hormone GIP in the proximal duodenum or jejunum and stomach. In healthy people, it takes about 7 minutes for a half-life to occur, while in people escorted by type 2 diabetes, it takes only 5 minutes (Ibrahim M et al., 2020).

Because of brief half-lives, the particular incretins are promptly broken down by DPP-4 after they are released minutes after eating. DPP-4 inhibitors lower postictal and fasting hyperglycemia next to inhibiting the DPP-4 enzyme, which raises GLP-1 and GIP levels. GLP-1 and GIP levels are then raised by increased beta-cell insulin production in the pancreas.

Adverse effects

At the moment that taking medication from the DPP-4 drug class, that place an increased fear about low blood sugar in those who are before now gaining sulphonylureas. Nasopharyngitis, headache, nausea, heart failure, hypersensitivity, with skin reactions are a few of the negative effects.

The U.S. Food and Drug Administration (FDA) has issued a warning regarding the possibility of severe and incapacitating joint pain from some type 2 diabetes treatment, including sitagliptin, Saxagliptin, linagliptin, and Alogliptin. All medications in the dipeptidyl peptidase-

4 (DPP-4) inhibitors pharmacological family now carry a current Caution and Safety measure on this risk on their labels, according to FDA. Studies examining the fear of atrophic arthritis between DPP-4 inhibitor users, however, have not proven conclusive.

Inflammatory bowel illness, namely ulcerative colitis, was linked to an increased chance of developing, according to a 2018 observational investigation. This risk peaked subsequent to three to four years of utilization and began to decline in subsequent four years (Drucker DJ et al., 2006).

While balancing metformin monotherapy via dipeptidyl peptidase-4 inhibitors well medical care of type 2 diabetes, a 2020 Cochrane systematic inquiry did not discover sufficient proof of a reduction in loss of life, important disadvantageous incident, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, or accomplishment renal disorder (Nielsen HL et al., 2019).

Biguanide (AMP_k activator)

A group of drugs known as biguanides is prescribed to treat illnesses like type 2 diabetes with others. They function by lessening the volume of glucose produced during digestion. The only biguanide used to treat diabetes is metformin, which is currently available in the majority of countries. These medications are commonly recognized by the brand names Glucophage (metformin) and Glucophage XR (metformin extended-release). Riomet, Glumetza, and Fortamet are any about the others. Other diabetes drugs, similarly sulfonylureas, are also available in conjunction with metformin. The only drug in this category is metformin.

Mechanism of action

The most prevalent configuration of diabetes in the population is type 2 diabetes mellitus, which is also one of the leading causes of death. Type 2 diabetes mellitus is characterized by higher hepatic glucose production, which is mostly related to an expansion within gluconeogenesis, insulin resistance, with cell dysfunction.

Since more than 70 years ago, biguanides have been used to treat type 2 diabetes, with metformin, which is taken by more than 150 million people each year, the most commonly prescribed oral anti-diabetic medication surrounded by the world. Metformin prevents weight gain and does not consequence surrounded by hypoglycemia, which is frequently linked to the utilization of other anti-diabetic medications. Furthermore, metformin may be useful during medical care for diseases like nephropathy and polycystic ovary syndrome, which are frequently linked to diabetes or insulin resistance. The fundamental mechanism of the action of metformin is without moving unknown, despite the fact that its pleiotropic features indicate that the medication affects various tissues.

Adverse effects

Type 2 diabetes is treated with the prescription medication metformin. It belongs to a grouping of drugs known as biguanides. Blood sugar levels surrounded by humans in the company of type 2 diabetes rise faster than usual. Diabetes is not cured with metformin. As opposed to that, it aids in bringing your blood sugar volume down to a safe level.

Although the FDA has not yet approved metformin as the medical care for polycystic ovary syndrome (PCOS), it is frequently prescribed as this set-up is off-label. Metformin's adverse effects might range from minor to severe. The larger part of adverse effects is minor and largely has an impact on the digestive system. Even if they are less frequent, severe side effects such as lactic acidosis needs to be treated right away (Maruthur NM et al., 2016).

Thiazolidinedione ($PPAR_{\gamma}$ activator)

Thiazolidinediones are drugs that are used to control and treat type 2 diabetes mellitus. These drugs could be regulating nuclear transcription and increase insulin sensitivity. This exercise demonstrates the benefits of thiazolidinediones as effective medications for controlling type 2 diabetes as well as their mode of action and contraindications. The only drug in this category is Pioglitazone (Shurrab NT et al., 2020).

Mechanism of action

The nuclear receptor known as peroxisome proliferator-activated receptor-gamma ($PPAR_{\gamma}$-gamma), which is complexed with retinoid X-receptor, is a site of Thiazolidinedione binding (RXR). They alter the $PPAR_{\gamma}$ -RXR complex to grow insulin signaling by promoting the binding of lipoprotein lipase, fatty acid transporter protein, adipocyte fatty acid-binding protein, Glut - 4, phosphoenolpyruvate carboxy kinase, malic enzyme, and other proteins to DNA.

Adverse effects

I. Fatal hepatotoxicity.
II. Oral contraceptive levels are decreased with concomitant administration.
III. Weight gain.
IV. Hypoglycemia.
V. Liver dysfunction.
VI. Fractures.
VII. Bladder cancer.

α-Glucosidase inhibitors

Modern oral anti-diabetic medications known as α-Glucosidase inhibitors (AGIs) have been licensed for both the inhibitor with medical care about type 2 diabetes mellitus. Acarbose, Voglibose, and miglitol are among the medications in this class. They are suitable for usage both alone and inside a mixture escorted by other treatments because of their outstanding safety and tolerability and moderate efficacy. This class of medications is distinct because it’s gastrointestinal (GI)-based, insulin- and glucose-independent mode of action and therapeutic aim of postprandial hyperglycemia (PPG). Its proof of undisputed cardiovascular advantages is another distinctive quality. This class includes Acarbose, Miglitol, Voglibose (Lin Y et al., 2021).

Mechanism of action

Alpha-glucosidase inhibitors prevent the small intestine from absorbing carbs. They compete with one another to prevent the enzymes that change complicated, non-absorptive carbohydrates into simple, absorbable ones. Glucoamylase, sucrase, maltase,

and isomaltose enzymes are among them. They lessen the expansion with postprandial blood glucose concentrations by roughly 3 mmol/l by delaying carbohydrate absorption.

Adverse effects

Alpha-glucosidase inhibitors' gastrointestinal adverse effects are the majority often reported ones. These are brought on by the colon's bacteria degrading undigested carbohydrates, which results in an excessive build-up of gas. The most often reported adverse effect, occurring in roughly 78% of instances, is flatulence. Additionally, possible symptoms include diarrhea and stomach ache. There can be rare circumstances where doing acarbose (but not other AGIs) increases your fear of contracting hepatitis. These diminish over time, and by beginning escorted by a small dose, their harshness can be further diminished. These negative consequences may become more pronounced with a diet high in carbohydrates (Khursheed R et al., 2019).

Sod-glucose cotransport-2 (SGLT-2) inhibitor

Surrounded by separate with type 2 diabetes, the utilization of SGLT2 inhibitors, a family of prescription drugs, in conjunction escorted by diet and exercise has been approved by the FDA. Canagliflozin, dapagliflozin, and empagliflozin are some of the drugs within the SGLT2 inhibitor class. This class includes Dapagliflozin and Canagliflozin.

Mechanism of action

The sole way SGLT2 inhibitors lower plasma glucose levels is at the side of averting the reabsorption of filtered glucose, which decreases as plasma levels do. While a result, unless additional therapies are being used that would normally produce hypoglycemia, they usually do not. Weight and blood pressure are only slightly reduced escorted by SGLT2 inhibitors.

Dopamine D2 agonist

A medication that acts as a dopamine D2 receptor agonist and is cast-off to medicate early Parkinson's syndrome also galactorrhea brought on by hyperprolactinemia with further set-up related to prolactin. The only drug in this category is Bromocriptine (Ali N, 2011).

Mechanism of action

Dopamine is released from the hypothalamus. It binds to dopamine d2 receptors and inhibits the synthesis and secretion of prolactin from the anterior pituitary gland. Dopamine agonist to treat hyperprolactinemia (Molitch ME, 2001).

Adverse effects

A dopamine receptor agonist is taken orally; bromocriptine is primarily cast-off to medicate Parkinson's disease. However, it also inhibits the declaration of prolactin and growth hormone, which has led to its usage in medical care for acromegaly, infertility, and galactorrhea. Bromocriptine therapy has been linked to some number of uncommon cases of acute liver injury and is identified escorted by temporary blood enzyme increases that occur while receiving treatment (Hansen KA, 2006).

Available medicine in the world and India

A wide range of brand-new drugs has been created to treat and manage diabetes, a condition where too much sugar increases in the blood. Insulin, a hormone such aids in processing blood sugar so it can be used as fuel, is not manufactured in the body at all or in very small amounts in people escorted by like type 1 diabetes. The body improperly uses insulin when a person has type 2 diabetes. The intent of these drugs is to aid in regulating the body's glucose or blood sugar levels. Among the available medications are synthetic insulin, pills taken orally, and needle-administered injectables.

The most recent diabetes treatments are discussed surrounded by this article. Furthermore, it describes the suggested dosage and any possible adverse effects (Sahakian N et al., 2022).

New Oral Diabetes Medications

People having Type 2 diabetes can manage their blood sugar levels escorted by the aid of oral diabetes medicines. There are many different kinds. It's possible that you'll require to take several different types, also as insulin and pills. Your healthcare professional can go over your alternatives with you, along with the benefits and drawbacks of each.

(I) Steglatro (Ertugliflozin)

Ertugliflozin, known as Steglatro, received approval in 2017. In order to lower the blood sugar levels of adults escorted like type 2 diabetes, this medication is prescribed made up of two diets and exercise. For people with like type 1 diabetes, it is not advised.

As a result of this medication:

- It is advised to take 5mg once daily. This could be taken in the morning with or without breakfast (Clore JN et al., 2009).
- If more glycemic control is required, the dosage can be raised to 15 mg at one time daily (Mah PM et al., 2004).

(II) Glyxambi (Empagliflozin & Linagliptin)

Glyxambi, which consists of the medications empagliflozin and linagliptin, received approval in 2015. To make better glycemic control in like type 2 diabetic people, this treatment is cast-off with exercise and a healthy diet (Hanefeld M et al., 2004).

Be aware of:

- 10 mg of empagliflozin and 5 mg of linagliptin taken one time in the morning is the suggested dosage (Van Ruiten CC et al., 2022).
- The dosage can at that moment be increased to 25 mg of empagliflozin and 5 mg of linagliptin once a day.

(III) Synjardy (Empagliflozin and Metformin Hydrochloride)

The medication Synjardy, which contains the active ingredients empagliflozin and metformin hydrochloride, was authorized in 2015. The present drug assists people with like type 2 diabetes in lowering their sugar levels of blood together with exercise and diet. Actually, should be consumed with food twice a day. Lactic acidosis is mentioned in the medication's warning label.

(IV) Segluromet (Ertugliflozin and Metformin Hydrochloride)

The medication Segluromet, which contains the active ingredients ertugliflozin and metformin hydrochloride, was authorized in 2017. It helps persons with type 2 diabetes better regulate their sugar levels of blood when combined with exercise and a healthy diet. It might be suggested for people who have never seen improved glycemic control with previous drugs. Lactic acidosis is mentioned in the medication's warning label.

(V) Kerendia (Finerenone)

It was authorized for Kerendia (Finerenone) in July 2021. Adults with like type 2 diabetes can use it to treat chronic renal disease or kidney function loss. In addition, it seeks to lower the fear of kidney failure, heart attacks, and deaths from cardiac diseases.

Be aware of:

- Once daily administration is advised at either a dosage of 20 mg after four weeks, if necessary, or 10 mg first.
- Sodium levels low and blood pressure of low are likely side effects. High amounts of the chemical potassium in the human body are another negative impact that can cause uncomfortable feelings.

Novel Insulin Treatments:

Diabetes of both types 1 and 2 can be managed with the aid of insulin. Transferring blood sugar within the tissues, where it can be utilized as energy, aids in stabilizing sugar levels of blood. Moreover, it can prevent the body beginning at producing more sugar. The time a drug waits in the body and the time it takes to start acting are different for each prescription. To administer insulin, use a pen or syringe and inject it under the layer of the skin.

(I) Afrezza (Inhaled Insulin)

Inhaled insulin, known as Afrezza, was given the go-ahead in 2014 to assist adults with like type 1 and type 2 diabetes control high blood sugar levels. It's a drug that works quickly and is inhaled into the lungs.

To remember:

- The usage of this drug in people with type 1 diabetes should be done in conjunction with long-acting insulin (Søfteland E et al., 2017).
- Anyone with a lung disease should refrain from using it.

(II) Tresiba (Insulin Degludec Injection)

In 2015, Tresiba (insulin degludec injection) received approval. For people with like type 1 or type 2 diabetes, it's a long-acting insulin (injectable) that helps with glycemic control. It's not advised for the management of diabetic ketoacidosis (Grajower MM et al., 2019).

The dosage varies depending on:

- Kind of diabetes.
- The outcome of measuring blood sugar.
- Metabolic requirements, either how the human body converts food into energy.

- Controlling blood sugar Objectives.

(III) Toujeo (Insulin Glargine Injection)

Long-acting insulin (injectable) called Toujeo was authorized in 2015. To enhance glycemic, management in adults with like type 1 or type 2 diabetes. The treatment is given one time day-to-day at the very same time (Thalange N et al., 2019).

Dosage changes depending on (Farmer A et al., 2005):

- Diabetes disease kind.
- The outcomes of measuring blood sugar.
- Metabolic requirements.
- Controlling blood sugar objectives.

CONCLUSION:

Diabetes is a slowly fatal disease for which there are no recognized cures. Through appropriate Knowledge and prompt Treatment, its problems can be minimized. Additionally, diabetic long-term consequences and disease severity are decreased by exercise. In Reality, if incorporated into daily life, a well-planned and consistent fitness routine can be highly beneficial for those with diabetes. Without using additional medications, exercise provides the advantage of regulating blood sugar levels. Heart attack, Kidney damage, and blindness are three serious side effects. In order to prevent complications, it is conclusive to strictly regulate the blood glucose levels of the patients. One of the challenges in maintaining strict control over blood glucose levels is that such efforts may result in hypoglycemia, which causes considerably more serious problems than an elevated blood glucose level. This essay aims to elevate blood overview of the state of diabetes research at the moment. In the twenty-first century, diabetes is a very difficult research subject.

ACKNOWLEDGMENTS

The authors are very much thankful to the Bengal School of Technology, Seacom Skill University, Eminent College of Pharmaceutical Technology, and Adamas University for providing the necessary facilities and infrastructure to complete this article.

CONFLICT OF INTEREST

Declared none.

FUNDING

Nil

REFERENCE:

Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and diabetes. *Rheumatic Disease Clinics* 2012; 38(1): 179-206.

Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. *The American journal of gastroenterology* 2013; 108(1): 18-29.

Tan AH, Lim SY, Lang AE. The microbiome–gut–brain axis in Parkinson disease—from basic research to the clinic. *Nature Reviews Neurology* 2022 Aug; 18(8): 476-95.

Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. *The lancet Diabetes & endocrinology* 2014; 2(1): 56-64.

Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, Aksut B, Alam T, Alam K, Alla F. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. *Journal of the American college of cardiology* 2017; 70(1): 1-25.

Hruby A, Hu FB. The epidemiology of obesity: a big picture. *Pharmacoeconomics* 2015; 33 (7): 673-689.

Shanmugam VU, Shanmugam R, Mariappan RG, Swaminathan B, Nandipati S, John P. Audiological profile in diabetes mellitus in correlation with inflammatory markers. *Journal of Evolution of Medical and Dental Sciences* 2014; 3(55): 12655-65.

Nahar K, Kaushik S. Homoeopathy for management of type 2 diabetes mellitus in a patient of major depressive disorder-A case report. *Indian Journal of Research in Homoeopathy* 2021; 15(1): 55-62.

Singh N, Kesherwani R, Tiwari AK, Patel DK. A review on diabetes mellitus. *The Pharma Innovation* 2016; 5(7, Part A):36-46

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature reviews endocrinology* 2018; 14(2): 88-98.

Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. *International journal of molecular sciences* 2018; 19(11): 3342.

Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. *Nature Reviews Endocrinology* 2017; 13(11): 674-686

Steenkamp DW, Alexanian SM, Sternthal E. Approach to the patient with atypical diabetes. *CMAJ*. 2014;186(9): 678-684.

Szablewski L. Role of immune system in type 1 diabetes mellitus pathogenesis. *International immunopharmacology* 2014; 22(1): 182-191.

Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. *Annals of the New York Academy of Sciences* 2002; 967(1): 363-378.

Nair S, Ormazabal V, Lappas M, McIntyre HD, Salomon C. Extracellular vesicles and their potential role inducing changes in maternal insulin sensitivity during gestational diabetes mellitus. *American Journal of Reproductive Immunology* 2021; 85(2): 13361-13369.

Ahmed, R. G., ed. Diabetes and Its Complications. *BoD–Books on Demand* 2018.

Castellanos L, Tuffaha M, Koren D, Levitsky LL. Management of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus. *Pediatric Drugs* 2020; 22(4): 357-367.

Bastaki S. Diabetes mellitus and its treatment. *Dubai Diabetes and Endocrinology Journal* 2005; 13: 111-134.

Hiriart M, Velasco M, Larqué C, Diaz-Garcia CM. Metabolic syndrome and ionic channels in pancreatic beta cells. *Vitamins & Hormones* 2014; 95: 87-114.

Kutlubay Z, Sevim A, Engin B, Tüzün Y. Photodermatoses, including phototoxic and photoallergic reactions (internal and external). *Clinics in dermatology* 2014; 32(1): 73-79.

Allen TW. Medi-notes. *The Journal of the American Osteopathic Association* 1992; 92(1): 16-41.

Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. *Journal of Diabetes and its Complications* 2003; 17(2): 11-15.

Ibrahim M, Baker J, Cahn A, Eckel RH, El Sayed NA, Fischl AH, Gaede P, Leslie RD, Pieralice S, Tuccinardi D, Pozzilli P. Hypoglycaemia and its management in primary care setting. *Diabetes/Metabolism Research and Reviews* 2020; 36(8): 3332-3341.

Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *The Lancet* 2006; 368(9548): 1696-1705.

Nielsen HL, Dalager-Pedersen M, Nielsen H. Risk of inflammatory bowel disease after Campylobacter jejuni and Campylobacter concisus infection: a population-based cohort study. *Scandinavian Journal of Gastroenterology* 2019; 54(3): 265-272.

Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. *Annals of internal medicine* 2016; 164(11): 740-751.

Shurrab NT, Arafa ES. Metformin: A review of its therapeutic efficacy and adverse effects. *Obesity medicine* 2020; 17: 100186-100194.

Lin Y, Li Y, Zeng Y, Tian B, Qu X, Yuan Q, Song Y. Pharmacology, toxicity, bioavailability, and formulation of magnolol: An update. *Frontiers in Pharmacology* 2021; 12: 632767-632779.

Khursheed R, Singh SK, Wadhwa S, Kapoor B, Gulati M, Kumar R, Ramanunny AK, Awasthi A, Dua K. Treatment strategies against diabetes: Success so far and challenges ahead. *European journal of pharmacology* 2019; 862: 172625-172634.

Ali N. Diabetes and you: A comprehensive, holistic approach. *Rowman & Littlefield Publishers* 2011.

Molitch ME. Disorders of prolactin secretion. *Endocrinology and metabolism clinics of North America*. 2001; 30(3): 585-610.

Hansen KA. Hyperprolactinemia and the dopamine receptor. *US Endocrinology*. 2006; 1: 74-76.

Sahakian N, Castinetti F, Brue T, Cuny T. Current and Emerging Medical Therapies in Pituitary Tumors. *Journal of Clinical Medicine* 2022; 11(4): 955- 961.

Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. *Endocrine practice* 2009; 15(5): 469-474.

Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT, Ross RJ. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. *Clinical endocrinology* 2004; 61(3): 367-375.

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. *Diabetes care* 2004; 27(1):141-147.

Van Ruiten CC, Veltman DJ, Schrantee A, van Bloemendaal L, Barkhof F, Kramer MH, Nieuwdorp M, IJzerman RG. Effects of dapagliflozin and combination therapy with exenatide on food-cue induced brain activation in patients with type 2 diabetes. *The Journal of Clinical Endocrinology & Metabolism* 2022; 107(6): 2590-2599.

Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. *Diabetes Care* 2017; 40(2): 201-209.

Grajower MM, Horne BD. Clinical management of intermittent fasting in patients with diabetes mellitus. *Nutrients* 2019; 11(4): 873-886.

Thalange N, Biester T, Danne T. Clinical use of degludec in children and adolescents with T1D: a narrative review with fictionalized case reports. *Diabetes Therapy* 2019; 10(4): 1219-1237.

Cahn A, Miccoli R, Dardano A, Del Prato S. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. *The Lancet Diabetes & Endocrinology* 2015; 3(8): 638-652.

Farmer A, Gibson O, Hayton P, Bryden K, Dudley C, Neil A, Tarassenko L. A real-time, mobile phone-based telemedicine system to support young adults with type 1 diabetes. *Informatics in primary care* 2005;13(3): 25-36.

Nishimura R, Taniguchi M, Takeshima T, Iwasaki K. Efficacy and safety of metformin versus the other oral antidiabetic drugs in Japanese type 2 diabetes patients: a network meta-analysis. *Advances in therapy* 2022; 39(1): 632-654.

Lupattelli A, Barone-Adesi F, Nordeng H. Association between antidepressant use in pregnancy and gestational diabetes mellitus: Results from the Norwegian Mother, Father and Child Cohort Study. *Pharmacoepidemiology and Drug Safety* 2022; 31(2): 247-256.